Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET

Company Participants

Neda Safarzadeh - Head of Investor Relations, Public Relations and Marketing
Joseph Payne - President and Chief Executive Officer
Andy Sassine - Chief Financial Officer
Steve Hughes - Chief Medical Officer
Pad Chivukula - CSO and COO

Conference Call Participants

Yasmeen Rahimi - Piper Sandler
Nick Abbott - Wells Fargo
Seamus Fernandez - Guggenheim
Kumar Raja - Brookline Capital Markets

Operator

Greetings, and welcome to the Arcturus Therapeutics Second Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce Neda Safarzadeh, Senior Director and Head of Investor Relations, Public Relations and Marketing. Thank you. You may begin.

Neda Safarzadeh

Thank you, operator, and good afternoon, everyone. We are joined today by Joseph Payne, President and CEO; Andy Sassine, CFO; Dr. Pad Chivukula, CSO and COO; and Dr. Steve Hughes, our Chief Medical Officer.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and any responses to questions on this conference call constitute forward-looking statements that involve substantial risks and uncertainties for purposes of the Safe Harbor provided by the Private Securities Litigation Reform Act of 1995.

Any statements other than the statements of historical facts included in this communication, including those regarding our planned, anticipated or potential development, manufacturing and commercialization activities or events including with respect to funding, initiation, design or completion of clinical trials the likelihood of success of company's Coronavirus COVID-19 vaccine candidate or other product candidates, the company's manufacturing and other operations, and the company's current and future cash and financial position are forward-looking